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Abstract
Background: FibroTest (FT) is the most frequently used serum fibrosis marker and consists of an algorithm of five
fibrosis markers (alfa2-macroglobulin, apolipoproteinA1, haptoglobin, GGT, bilirubin). The Enhanced Liver Fibrosis
(ELF) test consists of an algorithm of three fibrosis markers (hyaluronic acid, amino-terminal propeptide-of-type-III-
collagen, tissue-inhibitor of matrix-metaloproteinase-1). While a systematic review has shown comparable results for
both individual markers, there has been no direct comparison of both markers.
Methods: In the present study, the ELF-test was analyzed retrospectively in patients with chronic liver disease, who
received a liver biopsy, transient elastography (TE) and the FibroTest using histology as the reference method.
Histology was classified according to METAVIR and the Ludwig’s classification (F0-F4) for patients with chronic
hepatitis C and B virus (HCV, HBV) infection and primary biliary cirrhosis (PBC), respectively.
Results: Seventy-four patients were analysed: 36 with HCV, 10 with HBV, and 28 with PBC. The accuracy (AUROC)
for the diagnosis of significant fibrosis (F≥2) for ELF and FibroTest was 0.78 (95%CI:0.67-0.89) and 0.69 (95%-CI:0.57-
0.82), respectively (difference not statistically significant, n.s.). The AUROC for the diagnosis of liver cirrhosis was 0.92
(95%CI:0.83-1,00), and 0.91 (95%CI:0.83-0.99), respectively (n.s.). For 66 patients with reliable TE measurements the
AUROC for the diagnosis of significant fibrosis (cirrhosis) for TE, ELF and FT were 0.80 (0.94), 0.76 (0.92), and 0.67
(0.91), respectively (n.s.).
Conclusion: FibroTest and ELF can be performed with comparable diagnostic accuracy for the non-invasive
staging of liver fibrosis. Serum tests are informative in a higher proportion of patients than transient elastography.
Background
For different causes of chronic liver disease assessment of
liver fibrosis is important to estimate the prognosis and to
determine surveillance strategies for liver cancer. In addi-
tion, for chronic viral hepatitis the degree of liver fibrosis
is one important parameter for decision on antiviral ther-
apy [1]. At present, liver biopsy is still most commonly
used as reference standard for the assessment of liver
fibrosis. However, it is an invasive method associated with
patient discomfort and in rare cases with serious compli-
cations [2]. In addition, the accuracy of liver biopsy is
limited due to sampling error and significant intra- and
inter-observer variability in histological staging [3,4].
Therefore, research has focused on the evaluation of non-
invasive methods for the assessment of liver fibrosis.
Transient elastography (FibroScan, Echosens, France,
[TE]) [5,6] and the serological fibrosis marker FibroTest
(Biopredictive, France, [FT]) [7,8] have been evaluated
most frequently. FibroTest consists of an algorithm of five
fibrosis markers (alfa2-macroglobulin, apolipoproteinA1,
haptoglobin, GGT, bilirubin). The Enhanced Liver Fibrosis
Test (ELF, Siemens Diagnostics) [9,10] consists of an algo-
rithm of three fibrosis markers (hyaluronic acid, amino-
terminal propeptide of type III collagen, tissue inhibitor of
matrix metaloproteinase 1). The aim of the present study
was to analyze the ELF test using frozen serum samples
from patients with chronic liver disease that received a
liver biopsy, transient elastography (TE) and the FibroTest
and to compare the results of the non-invasive tests using
histology as reference method.
Methods
The study period for sample acquisition was from
September 2005 to June 2008. The Serum bank of the
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J.W. Goethe-University Hospital was checked for serum
of patients with chronic liver disease, who received a
liver biopsy, transient elastography and FibroTest. The
patients were included in the present study, if frozen
serum was available dated around the time of the per-
formance of FibroTest. The time interval between sam-
ple acquisition for the FibroTest and ELF was up to one
week without any therapeutic interventions between the
performances of the two tests. As the mean progression
rate of liver fibrosis in untreated patients was estimated
0.085-0.120 fibrosis stages on the Metavir scoring sys-
tem per year [11] a time interval between liver biopsy
and the performance of the non-invasive methods of up
to 12 months was accepted for enrollment in the pre-
sent study. The time interval between liver biopsy and
study inclusion ranged from 0 to 10 months (mean 10 ±
10 weeks, median 3 weeks). The indication for liver
biopsy was the determination of histological fibrosis and
inflammation. Written informed consents were obtained
from all patients and the study was conducted in agree-
ment with the Declaration of Helsinki and Good Clinical
Practice guidelines (ethics committee of Johann Wolf-
gang Goethe-University).
Liver Histology
Liver biopsy specimens were fixed in 4%-buffered for-
malin and embedded in paraffin. Two-micrometer-
thick sections were stained with hematoxylin-eosin,
Perls-iron-stain, dPAS (periodic-acid-Schiff after diges-
tion with diastase), Masson-Trichrome. All biopsy spe-
cimens were analyzed by an experienced pathologist
blinded to the clinical results of the patients. Liver
fibrosis stages were evaluated semi-quantitatively
according to the Metavir scoring-system [12] for
patients infected with chronic hepatitis B or C. Liver
fibrosis was staged on a F0-F4 scale: F0-no fibrosis,
F1-portal fibrosis without septa, F2- portal fibrosis
with few septa, F3- numerous septa without cirrhosis,
F4-cirrhosis. In patients with PBC histological-stage
was determined according to the Ludwig’s classifica-
tion[13]: stage I = inflammation and/or abnormal con-
nective tissue is confined to portal triads; stage II =
the number of normal bile ducts is reduced, the
inflammation and/or fibrosis is confined to portal and
periportal areas; stage III = fibrous septa link adjacent
portal triads (bridging fibrosis); stage IV = cirrhosis
with regenerative nodules. No stage 0 = no inflamma-
tion/fibrosis exists in the Ludwig’s classification, since
stage I is part of the diagnosis of PBC. The biopsies
were judged as adequate, if the number of portal
tracts was at least 6 and the length of liver biopsy at
least 1 cm. The mean length of the included liver
biopsies was 22.3 ± 9.3 mm (median 20 mm, range
10-54 mm).
Blood Markers
The following blood parameters were determined after
overnight fasting in the same laboratory on the same
day as transient elastography in all patients: aspartate
aminotransaminase (AST), alanine aminotransaminase
(ALT), g-glutamyl transpeptidase, alkaline phosphatase,
total bilirubin, platelet count, a2-macroglobulin, apoli-
poprotein A1, and haptoglobin. Enzymatic activity was
measured at 37°C according to International Federation
of Clinical Chemistry standards.
The laboratory followed the pre-analytical and analyti-
cal recommendations required to obtain the fibrosis
marker score FibroTest® (Biopredictive, France) [14].
The FibroTest was computed on the Biopredictive web-
site http://www.biopredictive.com. The security algo-
rithms on the industrial website permitting to exclude
patients with high risk profile of false positive/negative
were respected [15].
Frozen serum of the above patients taken around the
same time (stored at -80°C) was send to an indepen-
dent reference laboratory (iQur Limited, Southampton,
UK). Serum samples were analyzed for levels of tissue
inhibitor of matrix metalloproteinase 1 (TIMP-1), hya-
luronic acid (HA), and amino-terminal propeptide of
type III collagen (P3NP) using the proprietary assays
developed for ELF test by Siemens Healthcare Diag-
nostics Inc. (Tarrytown, New York USA). Assays were
performed on an Immuno-1 auto-analyser (Siemens
Healthcare Diagnostics Inc, Tarrytown, New York,
USA). Results were entered into the established algo-
rithm [10] and expressed as discriminant scores (DS) =
-7.412 + (ln(HA)*0.681) + (ln(P3NP)*0.775) + (ln
(TIMP1)*0.494) +10 for comparison to Metavir and
Ludwig’s histological staging.
Transient Elastography
Transient Elastography (TE) was performed using
FibroScan® (Echosens, France). This machine is
equipped with a probe including an ultrasonic transdu-
cer mounted on the axis of a vibrator. A vibration trans-
mitted from the vibrator towards the tissue induces an
elastic shear wave that propagates through the tissue.
These propagations are followed by pulse-echo ultra-
sound acquisitions and their velocity is measured which
is directly related to tissue stiffness. Results are
expressed in kilopascal. Details have been described in
previous studies [16]. The examination was performed
on the right lobe of the liver through the intercostal
space. After the area of measurement was located, the
examiner pressed the button of the probe to start the
acquisition. The measurement depth was between 25
and 65 mm. As suggested by the manufacturer ten suc-
cessful acquisitions were performed on each patient.
Only TE-results obtained with 10 valid measurements,
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with a success-rate of at least 60% and an interquartile
range ≤30% were considered reliable. FibroScan failure
is defined when less than 10 valid measurements are
obtained.
Statistical Analysis
Statistical analysis was performed using BiAS for
Windows (version 9.04, epsilon 2009, Frankfurt, Ger-
many). Correlations were assessed by Spearmans correla-
tion coefficient. The diagnostic performance of ELF,
FibroTest and TE was assessed using receiver-operating-
characteristic (ROC)-curves. The ROC-curve represents
a plot of sensitivity versus 1-specificity for all possible
cut-off values for prediction of the different fibrosis
stages, respectively. The areas-under-the-ROC-curves
(AUROC) as well as 95%-CI of AUROC were calculated.
AUROC values for different diagnostic criteria for the
same data set were compared with the non-parametric
DeLong-test. Note that AUROC values for the different
methods are correlated and that this test accounts for
such correlations. Therefore, it may find significant dif-
ferences in diagnostic accuracy even when confidence
intervals of the single AUROC values, which ignore these
correlations, are overlapping. Since two different fibrosis
staging systems (Metavir and Ludwig’s) were used to
classify histology, and both systems use scores ranging
from 0 to 4, the scoring systems were pooled for the
overall calculation of the mean-AUROC. In case of diag-
nosing fibrosis stages greater than or equal 2 versus
stages less than 2, we also calculated the differences
between mean advanced, versus mean non-advanced
fibrosis stages (DANA)-adjusted AUROC according to
Poynard et al. [17] for a standardized DANA value of 2.5.
Note that this adjustment was only validated for HCV
patients and for FibroTest only. Assuming that, using
other methods (TE and ELF) and in other pathologies,
the spectrum bias has the same profile as for FT in HCV,
we extrapolated the algorithm to adjust all the AUROCs
in the present study.
Using cut-off values defined for the prediction of
fibrosis in previous studies, sensitivity, specificity, posi-
tive- and negative-predictive-values positive- and nega-
tive likelihood ratios were calculated for the present
study.
Results
Seventy-four patients were included in the analysis: 36
patients with HCV infection, 10 with HBV infection,
and 28 with PBC. Patients’ characteristics are shown in
table 1.
The Spearman correlation coefficient of FibroTest and
ELF with the different histological stages were 0.44, and
0.61, respectively (all p < 0.0001). The correlation coeffi-
cient between FibroTest and ELF was 0.62 (p < 0.0001).
The diagnostic accuracy (AUROC) for the diagnosis of
significant fibrosis (F≥2) for ELF and FibroTest was 0.78
(95%-CI: 0.67-0.89) and 0.69 (95%-CI: 0.57-0.82), respec-
tively (s. figure 1). The difference was not statistically sig-
nificant (p = 0.20). The AUROC for the diagnosis of
severe fibrosis (F≥3) was 0.79 (95%-CI: 0.67-0.91) and
0.72 (95%-CI: 0.60-0.84), respectively (p = 0.22). The
AUROC for the diagnosis of liver cirrhosis was 0.92
(95%-CI: 0.83-1.00) and 0.91 (95%-CI: 0.82-0.99), respec-
tively (p = 0.91) (s. figure 2). Details are shown in table 2.
Eight patients were excluded because of unreliable TE-
measurements (less than 10 valid measurements, success
rate <60%, or IQR >30%). Therefore only 66 patients
were available for the comparison of TE with FT and
Table 1 Patient’s characteristics
Characteristics Patients (n = 74)
Sex: 31 male/43 female patients
Age: mean±SD: 50 ± 13 years, median 50 years, range: 18-77 years
BMI: mean±SD: 25 ± 5 kg/m2, median: 25 kg/m2, range 17-36 kg/m2
AST: mean±SD: 42 ± 32 IU/L, median 31 IU/L, range: 21 - 207 IU/L
ALT: mean±SD: 56 ± 67 IU/L, median: 35.5 IU/L, range: 7 - 460 IU/L
GGT: mean±SD: 66 ± 79 IU/L, median: 39.5 IU/L, range 8 - 459 IU/L
Total bilirubin: mean±SD: 0.71 ± 0.42 mg/dL, median: 0.6 mg/dL, range: 0.2 - 2.4 mg/dL
Platelet count: mean±SD: 214 ± 75 × 103/mm3, median 226 × 103/mm3, range: 22-351 × 103/mm3
Histological Fibrosis stage
F0 4 patients
F1 21 patients
F2 18 patients
F3 20 patients
F4 11 patients
SD = standard deviation, pat. = patients; ULN = upper limit of normal. BMI = body mass index. AST = aspartate aminotransaminase. ALT = alanine
aminotransaminase. GGT = gamma-glutamyl transpeptidase. Normal value ALT and AST: female <35 U/l, male: <50 U/l; GGT female: <39 U/l, male: <66 U/l
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ELF. For these 66 patients the Spearman correlation coef-
ficient between TE, FibroTest and ELF with the different
histological stages were 0.58, 0.42, and 0.58, respectively
(p < 0.001). The correlation coefficient between TE and
FibroTest was 0.67 (p < 0.0001), between TE and ELF
0.65 (p < 0.0001), and between FibroTest and ELF 0.62
(p < 0.0001), respectively. For these 66 patients the
AUROC for the diagnosis of significant fibrosis for TE,
ELF and FT was 0.80, 0.76, and 0.67, respectively (p =
0.42 for TE vs ELF, p = 0.08 for TE vs FT, p = 0.23 for
ELF vs FT). The AUROC for the diagnosis of severe
fibrosis (F≥3) was 0.66, 0.69 and 0.63, respectively (p =
0.60 for TE vs ELF, p = 0.68 for TE vs FT, p = 0.35 for
ELF vs FT). And the AUROC for the diagnosis of liver
cirrhosis was 0.94, 0.92, and 0.91, respectively (p = 0.60
for TE vs ELF, p = 0.42 for TE vs FT, p = 0.66 for ELF vs
FT). Details are shown in table 2.
The diagnostic performance of FibroTest, ELF and
transient elastography in the prediction of significant
fibrosis (F≥2), severe fibrosis (F≥3), and cirrhosis using
cut-offs defined in previous studies are shown in table 3.
Discussion
At present, transient elastography and the serum marker
FibroTest are the most intensively evaluated non-inva-
sive methods for the assessment of liver fibrosis. The
results of the present study for transient elastography,
FibroTest and ELF are in accordance with the results of
previous studies [5-8,10,18]. However, the latter is of
more clinical importance for estimation of prognosis,
surveillance and treatment decisions before patients
develop liver cirrhosis [1]. Furthermore inter and intra-
observer discrepancies in histological classification of
lesser stages of fibrosis are more prevalent than for
higher stages and this may account for the observed
under performance of non-invasive tests when com-
pared to histology as a reference standard.
A systematic review has shown comparable results for
ELF and FibroTest but no direct comparison of both
markers had been performed before [19]. This is the
first study, comparing transient elastography, FibroTest
and ELF in the same study population. The results of
the three non-invasive methods using different
approaches were comparable for the diagnosis of signifi-
cant fibrosis and cirrhosis in the present study.
The ELF test was developed in an international multi-
center cohort study with 1021 subjects with chronic
liver disease using discriminant analysis to identify the
above mentioned algorithm having investigated specific
markers of matrix turnover as well as indirect markers
of liver function [10]. The ELF test was validated in
Non-Alcoholic Liver Disease in adults [20] and in chil-
dren [21], in PBC and hepatitis C [9,22]
One study [23] has compared the FibroTest with ELF
in a subgroup of patients infected with chronic hepatitis
C. In this study, instead of using the ELF assays for HA,
PIIINP and TIMP-1 that have been developed by Sie-
mens Healthcare Diagnostics specifically for use in the
ELF test; and instead of performing the assays on the
Immuno-1 auto-analyser on which the ELF test is cur-
rently validated and CE marked, the investigators used
alternative assays and performed manual testing. Thus
the method used by Cales et al. to measure the analytes
prior to incorporating results into the ELF algorithm
cannot be considered to be analogous with the present
study.
Figure 1 Receiver-operating characteristic (ROC) curves for
FibroTest and ELF for diagnosis of significant fibrosis (F ≥ 2)
Figure 2 Receiver-operating characteristic (ROC) curves for
FibroTest and ELF for diagnosis of liver cirrhosis (F = 4)
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In the study of Cales et al. Fibrometer, an algorithm of
direct and indirect markers was evaluated and compared
with other non-invasive markers in a validation group.
The authors suggest that the combination of both mar-
kers might increase certain advantages and limit other
disadvantages. However, no significant difference was
found between the Fibrometer, FibroTest and ELF as
performed by the authors in this study. Similar results
were found comparing ELF and TE in 80 patients with
hepatitis C with the same diagnostic accuracy for both
Table 2 Area under ROC-curve (95% Confidence intervall) for transient elastography, FibroTest, and ELF according to
Metavir/Ludwig’s fibrosis stage
Method F ≥ 2 (F2,3,4) F ≥ 2 adjusted*1 F ≥ 3 F = 4
n = 74 FibroTest 0.69
(0.57 - 0.82)
0.74
(0.62 - 0.87)
0.72
(0.60 - 0.84)
0.91
(0.83 - 0.99)
ELF 0.78
(0.67 - 0.89)
0.83
(0.72 - 0.94)
0.79
(0.67 - 0.91)
0.92
(0.83 - 1.00)
n = 66 Transient Elastography 0.80
(0.69 - 0.91)
0.85
(0.74 - 0.96)
0.66
(0.51 - 0.82)
0.94
(0.86 - 1.00)
FibroTest 0.67
(0.54 - 0.80)
0.72
(0.59 - 0.85)
0.63
(0.48 - 0.79)
0.91
(0.82 - 0.99)
ELF 0.76
(0.64 - 0.88)
0.81
(0.69 - 0.93)
0.69
(0.54 - 0.85)
0.92
(0.83 - 1.00)
*1Dana-adjusted AUROC according to Poynard et al.[17] for a uniform DANA of 2.5
Table 3 Diagnostic performance of FibroTest, ELF and Transient Elastography in the prediction of significant fibrosis
(F≥2), severe fibrosis (F≥3), and cirrhosis for all patients, for HCV patients only, and for PBC patients only
Test Diagnosis Fibrosis Stage Cut-off Sensitivity Specificity PPV NPV Positive LR Negative LR
FibroTest All patients [7] F ≥ 2 0.32 0.57 0.60 0.74 0.42 1.43 0.71
F ≥ 3 0.59 0.39 0.88 0.71 0.67 3.33 0.69
F = 4 0.73 0.64 0.90 0.54 0.93 6.68 0.40
HCV only [7] F ≥ 2 0.32 0.81 0.60 0.84 0.55 2.02 0.32
F ≥ 3 0.59 0.65 0.79 0.73 0.71 3.07 0.45
F = 4 0.73 0.67 0.81 0.54 0.88 3.60 0.41
PBC only [7] F ≥ 2 0.32 0.30 0.75 0.75 0.30 1.20 0.93
F ≥ 3 0.59 0.08 1.00 1.00 0.56 invalid 0.92
F = 4 0.73 0.00 0.96 0.00 0.96 0.00 1.04
ELF All patients [9,18] F ≥ 2 * 9.78 0.78 0.80 0.88 0.65 3.88 0.28
F ≥ 3 * 10.22 0.74 0.70 0.64 0.79 2.45 0.37
F = 4 * 10.31 0.91 0.62 0.29 0.98 2.39 0.15
HCV only [9] F ≥ 2 9.78 0.85 0.80 0.92 0.67 4.23 0.19
F ≥ 3 10.22 0.82 0.74 0.74 0.82 3.13 0.24
F = 4 10.31 0.89 0.63 0.44 0.94 2.40 0.18
PBC only [22] F ≥ 2 9.69 0.65 0.75 0.87 0.46 2.60 0.47
F ≥ 3 9.71 0.62 0.53 0.53 0.62 1.32 0.72
F = 4 9.89 1.00 0.52 0.07 1.00 2.01 0.00
TE All patients [32-34] F ≥ 2 * 7.20 kPa 0.64 0.76 0.85 0.50 2.71 0.47
F ≥ 3 * 12.50 kPa 0.50 0.87 0.74 0.70 3.80 0.58
F = 4 * 17.60 kPa 0.82 0.91 0.64 0.96 9.00 0.20
HCV only [33] F ≥ 2 7.10 kPa 0.79 0.50 0.79 0.50 1.58 0.42
F ≥ 3 9.50 kPa 0.67 0.79 0.71 0.75 3.17 0.42
F = 4 12.50 kPa 0.78 0.84 0.64 0.91 4.86 0.27
PBC only [34] F ≥ 2 7.30 kPa 0.39 1.00 1.00 0.31 invalid 0.61
F ≥ 3 9.80 kPa 0.25 0.91 0.75 0.53 2.75 0.83
F = 4 17.30 kPa 1.00 0.95 0.50 1.00 22.00 0.00
The cut-offs were evaluated in previous studies, the references are cited in the diagnosis column in brackets for all patients, for HCV, and PBC respectively and
can be found in the reference list. For all patients the individual cut-offs for HCV and PBC were used if available, and for HBV the cut-offs of TE were used from a
study [32] evaluating patients with different chronic liver diseases, and of ELF the cut-offs of HCV [9] were used. For FibroTest no cut-offs for PBC have been
evaluated, the cut-offs for viral hepatitis [7] were used, respectively
TE = transient elastography, PPV = positive predictive value, NPV = negative predictive value, LR = likelihood ratio
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methods (AUROC 0.91, 0.90 for cirrhosis and 0.82 for
>stage 2 fibrosis) [24].
Recently, a series of algorithms based on sequential
combination of non-invasive serum markers showed
93-95% accuracy in the detection or exclusion of signifi-
cant liver fibrosis and a reduction of 50% of liver biop-
sies in this subset of patients with HCV infection [25].
However, the combination of FibroTest and ELF has not
been evaluated yet. Further studies are needed to evalu-
ate the advantages and disadvantages of both markers
and in which situations they may substitute each other.
Using liver biopsy as a reference standard for the
evaluation of non-invasive methods and markers has
methodological limitations which may influence the
performance of these tests. The accuracy of liver
biopsy is limited due to intra- and inter-observer varia-
bility and sampling errors [3]. In a study on more than
10,000 virtual biopsies Bedossa et al. [3] showed that
liver fibrosis stage is correctly diagnosed in only 65%
of cases, if the biopsy is at least 15 mm long, in 75% if
it is at least 25 mm long and, that the optimal size
should be 40 mm. However, most biopsies even at spe-
cialist Hepatology centers do not fulfill these optimal
criteria [26].
Data analyzing the discordance of liver biopsy and the
panel marker FibroTest showed that this discordance
was highly attributable to biopsy in 5% and to the panel
marker in 2% (p = 0.03) [26]. The authors concluded
that these shortcomings of liver biopsy lead to underes-
timation of the diagnostic accuracy of non-invasive mar-
kers. A recent study has demonstrated that error in the
liver biopsy result itself makes it impossible to distin-
guish a perfect non-invasive marker from less valid
assays [27]. This supports the assumption that non-inva-
sive markers might be underestimated using liver biopsy
as reference method. The ultimate validation of liver
fibrosis as a marker of liver injury is its prognostic value
in terms of morbidity and mortality. In a study in
patients infected with chronic hepatitis C, FibroTest was
shown to have a 5-year prognostic value similar to that
of liver biopsy [15]. In addition, the FibroTest was
shown to accurately define 4-year prognosis in patients
infected with hepatitis B [28] and 10-year prognosis in
patients with alcoholic liver disease [29]. A study in
patients with PBC demonstrated a highly significant
relationship between the baseline ELF score and the
likelihood of developing a clinical complication over the
next 6 years [22], which was also shown in a mixed
etiology cohort of 500 patients [30].
For ultrasound based methods to measure liver fibro-
sis (transient elastography [FibroScan], and acoustic
radiation force impulse imaging [ARFI]) long-term fol-
low-up studies are not available yet [5,31]. Large, well-
conducted randomized trials with clearly defined
endpoints, i.e. assessing 5-year survival without compli-
cations related to liver disease (liver related death, liver
transplantation, hepatic decompensation, variceal bleed-
ing, hepatocellular carcinoma) are needed to compare
the non-invasive methods with each other and with liver
biopsy.
A limitation of the present study is its retrospective
analysis and the small study population, however, this is
the first study comparing an algorithm of indirect fibro-
sis markers (FibroTest), an algorithm of direct fibrosis
markers (ELF) using the approved and validated ELF
assay and analyzer and an ultrasound-based elastography
method in one and the same study population. Larger
prospective studies are necessary to confirm these
results. Another limitation of our analysis is the inclu-
sion of biopsies which are shorter than the usual stan-
dard of 15 mm, if at least 6 portal tracts were present.
Nevertheless, the exclusion of such short biopsies had
no significant effect on our results. In addition, the pre-
sent study was a comparative study between the differ-
ent non-invasive methods, where the quality of liver
biopsy affected all methods equally.
Conclusion
FibroTest and ELF can be performed with comparable
diagnostic accuracy for the non-invasive staging of liver
fibrosis.
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